Skip to main content

Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) (PACIFIC-4/RTOG-3515)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca Pharmaceuticals, LP

Start Date

January 2, 2020

End Date

March 29, 2022
 

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca Pharmaceuticals, LP

Start Date

January 2, 2020

End Date

March 29, 2022